Skip to main content

Advertisement

SpringerLink
Log in

Association of serum MIP-1α, MIP-1β, and RANTES with clinical manifestations, disease activity, and damage accrual in systemic lupus erythematosus

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

The aim of this study was to determine if macrophage inflammatory protein (MIP) 1α, MIP-1β, and RANTES (regulated upon activation normally T-cell expressed and secreted) serum concentrations are associated with clinical manifestations, disease activity, and damage accrual in patients with systemic lupus erythematosus (SLE). A cross-sectional study was performed in 62 SLE patients (per American College of Rheumatology criteria) participating in a longitudinal study and 20 healthy subjects. MIP-1α, MIP-1β, and RANTES serum concentrations were determined by enzyme-linked immunosorbent assay. Demographic parameters, clinical manifestations, serologic features, pharmacologic treatments, disease activity, and damage accrual were determined at study visit. Disease activity was assessed with the Systemic Lupus Erythematosus Activity Measure (SLAM), and disease damage was assessed with Systemic Lupus International Collaborating Clinic Damage Index (SDI). The relation between the variables was studied with the Student t test and the Pearson r correlation test. SLE patients were more likely to have higher concentrations of MIP-1β and RANTES than healthy individuals. In addition, they had a trend to have higher concentrations of MIP-1α. Patients with discoid lupus were more likely to have higher levels of MIP-1α. Elevation of MIP-1β correlated with higher SDI score. No association was found between serum chemokines levels and disease activity. In conclusion, SLE patients have higher serum levels of MIP-1β and RANTES than healthy individuals. MIP-1α is associated with discoid lupus, and MIP-1β correlates with damage accrual in SLE. This study suggests that chemokines may have a role in the pathogenesis of SLE.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Baggiolino M (1998) Chemokines and leukocyte traffic. Nature 392:565–568

    Article  CAS  Google Scholar 

  2. Springer TA (1994) Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76:301–314

    Article  PubMed  CAS  Google Scholar 

  3. Moser B, Wolf M, Walz A, Loetscher P (2004) Chemokines: multiple levels of leukocyte migration control. Trends Immunol 25:75–84

    Article  PubMed  CAS  Google Scholar 

  4. Ebert LM, Schaerli P, Moser B (2005) Chemokine-mediated control of T cell traffic in lymphoid and peripheral tissues. Mol Immunol 42:799–809

    Article  PubMed  CAS  Google Scholar 

  5. Eriksson C, Eneslätt K, Ivanoff J, Rantapää-Dahlqvist S, Sundqvist K-G (2003) Abnormal expression of chemokine receptors on T-cells from patients with systemic lupus erythematosus. Lupus 12:766–774

    Article  PubMed  CAS  Google Scholar 

  6. Robinson E, Keystone EC, Schall TJ, Gillett N, Fish EN (1995) Chemokine expression in rheumatoid arthritis (RA): evidence of RANTES and macrophage inflammatory protein (MIP)-1β production by synovial T Cells. Clin Exp Immunol 101:398–407

    Article  PubMed  CAS  Google Scholar 

  7. Hasegawa M, Sato S, Takehara K (1999) Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1 α (MIP-1α) and MIP-1β) in patients with systemic sclerosis: MCP-1 and MIP-1α may be involved in the development of pulmonary fibrosis. Clin Exp Immunol 117:159–165

    Article  PubMed  CAS  Google Scholar 

  8. Ye DQ, Yang SG, Li XP et al (2005) Polymorphisms in the promoter region of RANTES in Han Chinese and their relationship with systemic lupus erythematosus. Arch Dermatol Res 297:108–113

    Article  PubMed  CAS  Google Scholar 

  9. Lit LCW, Wong CK, Tam LS, Li EKM, Lam CWK (2005) Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus. Ann Rheum Dis 65:209–215

    Article  PubMed  CAS  Google Scholar 

  10. Chan RW, Lai FM, Li EK et al (2004) Expression of chemokine and fibrosing factor messenger RNA in the urinary sediment of patients with lupus nephritis. Arthritis Rheum 50:2882–2890

    Article  PubMed  CAS  Google Scholar 

  11. Tan EM, Cohen AS, Fries JF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277

    Article  PubMed  CAS  Google Scholar 

  12. Liang MH, Socher SA, Larson MG, Schur PH (1989) Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 32:1107–1118

    Article  PubMed  CAS  Google Scholar 

  13. Liang MH, Fortin PR, Isenberg DA, Snaith L (1991) Quantitative clinical assessment of disease activity in systemic lupus erythematosus: progress report and research agenda. Rheumatol Int 11:133–136

    Article  PubMed  CAS  Google Scholar 

  14. Stoll T, Stucki G, Malik J, Pyke S, Isenberg DA (1997) Association of the Systemic Lupus Erythematosus International Collaborating Clinics/American College of Rheumatology Damage Index with measures of disease activity and health status in patients with systemic lupus erythematosus. J Rheumatol 24:309–313

    PubMed  CAS  Google Scholar 

  15. Liao CH, Yao TC, Chung HT, See LC, Kuo ML, Huang JL (2004) Polymorphisms in the promoter region of RANTES and the regulatory region of monocyte chemoattractant protein-1 among Chinese children with systemic lupus erythematosus. J Rheumatol 31:2062–2067

    PubMed  CAS  Google Scholar 

  16. Kaneko H, Ogasawara H, Naito T et al (1999) Circulating levels of β-chemokines in systemic lupus erythematosus. J Rheumatol 26:568–573

    PubMed  CAS  Google Scholar 

  17. Meller S, Winterberg F, Gilliet M et al (2005) Ultraviolet radiation-induced injury, chemokines, and leukocyte recruitment. An amplification cycle triggering cutaneous lupus erythematosus. Arthritis Rheum 52:1504–1516

    Article  PubMed  CAS  Google Scholar 

  18. Wenzel J, Henze S, Wörenkämper E et al (2005) Role of the chemokine receptor CCR4 and its ligand thymus-and activation-regulated chemokine/CCL17 for lymphocyte recruitment in cutaneous lupus erythematosus. J Invest Dermatol 124:1241–1248

    Article  PubMed  CAS  Google Scholar 

  19. Schröder JM (1995) Cytokine networks in the skin. J Invest Dermatol 105:20S–24S

    Article  PubMed  Google Scholar 

  20. Tucci M, Barnes EV, Sobel ES et al (2004) Strong association of a functional polymorphism in the monocyte chemoattractant protein 1 promoter gene with lupus nephritis. Arthritis Rheum 50:1842–1849

    Article  PubMed  CAS  Google Scholar 

  21. Kim HL, Lee DS, Yang SH et al (2002) The polymorphism of monocyte chemoattractant protein-1 is associated with the renal disease of SLE. Am J Kidney Dis 40:1146–1152

    Article  PubMed  CAS  Google Scholar 

  22. Dai C, Liu Z, Zhou H, Li L (2001) Monocyte chemoattractant protein-1 expression in renal tissue is associated with monocyte recruitment and tubulo-interstitial lesions in patients with lupus nephritis. Chin Med J 114:864–868

    PubMed  CAS  Google Scholar 

  23. Schön MP, Zollner TM, Boehncke W-H (2003) The molecular basis of lymphocyte recruitment to the skin: clues for pathogenesis and selective therapies of inflammatory disorders. J Invest Dermatol 121:951–962

    Article  PubMed  Google Scholar 

  24. Mok CC, Lau CS (2003) Pathogenesis of systemic lupus erythematosus. J Clin Pathol 56:481–490

    Article  PubMed  CAS  Google Scholar 

  25. Yajima N, Kasama T, Isozaki T et al (2005) Elevated levels of soluble fractalkine in active systemic lupus erythematosus: potential involvement in neuropsychiatric manifestations. Arthritis Rheum 52:1670–1675

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Supported by National Institutes of Health (NIH)/Research Centers in Minority Institutions (RCMI) Clinical Research Infrastructure Initiative (RCRII) grant no. 1 G12 RR11108, NIH/RCMI grant no. G12 RR03035, and an unrestricted educational grant from Bristol Myers Squibb Company.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico

    Luis M. Vilá, María J. Molina & José J. Cruz

  2. Department of Internal Medicine, Universidad Central del Caribe, School of Medicine, Bayamón, Puerto Rico

    Angel M. Mayor

  3. Department of Microbiology and Immunology, Universidad Central del Caribe, School of Medicine, Bayamón, Puerto Rico

    Eddy Ríos-Olivares & Zilka Ríos

Authors
  1. Luis M. Vilá
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. María J. Molina
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Angel M. Mayor
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. José J. Cruz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eddy Ríos-Olivares
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zilka Ríos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Luis M. Vilá.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vilá, L.M., Molina, M.J., Mayor, A.M. et al. Association of serum MIP-1α, MIP-1β, and RANTES with clinical manifestations, disease activity, and damage accrual in systemic lupus erythematosus. Clin Rheumatol 26, 718–722 (2007). https://doi.org/10.1007/s10067-006-0387-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-006-0387-y

Keywords

Search

Navigation